Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure.

about

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure.

Item

http://www.wikidata.org/entity/Q49386937

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@en

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@nl

type

Item

label

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@en

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@nl

prefLabel

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@en

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@nl

P1476

Immunotherapy for Head and Nec ...... asing Health Care Expenditure.

@en

P2093

Cristina P Rodriguez

http://www.w3.org/2001/XMLSchema#string

Rafael Santana-Davila

http://www.w3.org/2001/XMLSchema#string

P2860

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Health outcomes in economic evaluation: the QALY and utilities.

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c

Predicting analysis times in randomized clinical trials with cancer immunotherapy

A systematic review of utility values for chemotherapy-related adverse events.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

P304

147-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2017-0527

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29192017

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5813756

http://www.w3.org/2001/XMLSchema#string